Improving the prognosis for patients with glioblastoma: The rationale for targeting Src

Journal of Neuro-Oncology

Volumn 95, Issue 2, 2009, Pages 151-163

  de Groot, John ^a   Milano, Vanessa ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Dasatinib; Glioblastoma; Src family of tyrosine kinases; Src inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CELECOXIB; DASATINIB; ERLOTINIB; IMATINIB; IRINOTECAN; LOMUSTINE; PROCARBAZINE; PROTEIN TYROSINE KINASE; TEMOZOLOMIDE; VINCRISTINE;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER INVASION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; DIARRHEA; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG TARGETING; FATIGUE; FLUID RETENTION; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; LEUKEMIA; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; NONHUMAN; PROGNOSIS; PROTEIN FUNCTION; RECURRENT CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 70350003803     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9916-2     Document Type: Review

References (101)

1. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109. doi: 10.1007/s00401-007-0243-4
2. Giese A, Bjerkvig R, Berens ME et al (2003) Cost of migration: Invasion of malignant gliomas and implications for treatment. J Clin Oncol 21:1624-1636. doi: 10.1200/JCO.2003.05.063
3. Martin GS (2001) The hunting of the Src. Nat Rev Mol Cell Biol 2:467-475. doi: 10.1038/35073094
4. Summy JM, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337-358. doi: 10.1023/ A:1023772912750
5. Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513-609. doi: 10.1146/ annurev.cellbio.13.1.513
6. Brabek J, Constancio SS, Siesser PF et al (2005) Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol Cancer Res 3:307-315. doi: 10.1158/1541-7786.MCR-05-0015
7. Dehm S, Senger MA, Bonham K (2001) SRC transcriptional activation in a subset of human colon cancer cell lines. FEBS Lett 487:367-371. doi: 10.1016/S0014-5793(00)02354-1
8. Dehm SM, Bonham K (2004) SRC gene expression in human cancer: The role of transcriptional activation. Biochem Cell Biol 82:263-274. doi: 10.1139/o03-077
9. Irby RB, Yeatman TJ (2000) Role of Src expression and activation in human cancer. Oncogene 19:5636-5642. doi: 10.1038/sj.onc.1203912
10. Courtneidge SA (2002) Role of Src in signal transduction pathways. The Jubilee Lecture. Biochem Soc Trans 30:11-17. doi: 10.1042/BST0300011
11. Frame MC (2002) Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta 1602:114-130
12. Niu G, Wright KL, Huang M et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008. doi: 10.1038/sj.onc.1205260
13. Abu-Ghazaleh R, Kabir J, Jia H et al (2001) Src mediates stimulation by vascular endothelial growth factor of the phosphorylation of focal adhesion kinase at tyrosine 861, and migration and anti-apoptosis in endothelial cells. Biochem J 360:255-264. doi: 10.1042/0264-6021:3600255
14. Tice DA, Biscardi JS, Nickles AL et al (1999) Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96:1415-1420. doi: 10.1073/pnas.96.4.1415
15. National Comprehensive Cancer Network (NCCN) (2008) Clinical practice guidelines in oncology: Central nervous system cancers, V.1.2008. Available at http://www.nccn.org/professionals/physician_gls/PDF/ cns.pdf. Accessed Sept 2008
16. Hentschel SJ, Sawaya R (2003) Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 10:109-114
17. Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/ or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333-343
18. Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329
19. Stewart LA (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018. doi: 10.1016/S0140-6736(02)08091-1
20. Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
21. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi: 10.1056/NEJMoa043331
22. Stupp R, Hegi ME, Van den Bent MJ et al (2006) Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist 11:165-180. doi: 10.1634/theoncologist.11-2-165
23. Hart MG, Grant R, Garside R et al (2008) Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst Rev CD007294
24. Prados MD, Lamborn K, Yung WK et al (2006) A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American brain tumor consortium study. Neuro Oncol 8:189-193. doi: 10.1215/ 15228517-2005-010
25. Brandes AA, Tosoni A, Basso U et al (2004) Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22:4779-4786. doi: 10.1200/JCO.2004.06.181
26. Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787. doi: 10.1212/01.wnl.0000304121.57857.38
27. Vredenburgh JJ, Desjardins A, Herndon JE et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729. doi: 10.1200/JCO.2007.12.2440
28. Reardon DA, Quinn JA, Vredenburgh J et al (2005) Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103:329-338. doi: 10.1002/cncr.20776
29. Yung WK, Mechtler L, Gleason MJ (1991) Intravenous carboplatin for recurrent malignant glioma: A phase II study. J Clin Oncol 9:860-864
30. Newton HB, Junck L, Bromberg J et al (1990) Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40:1743-1746
31. Rodriguez LA, Prados M, Silver P et al (1989) Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64:2420-2423. doi: 10.1002/ 1097-0142(19891215)64:12<2420::AID-CNCR2820641204>3.0.CO;2-B
32. Cloughesy T, Prados M, Wen PY et al. (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:2010b
33. Wong ET, Hess KR, Gleason MJ et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
34. O'Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004. doi: 10.1056/ NEJMoa022457
35. Louis DN (2006) Molecular pathology of malignant gliomas. Annu Rev Pathol 1:97-117. doi: 10.1146/annurev.pathol.1.110304.100043
36. Sanson M, Thillet J, Hoang-Xuan K (2004) Molecular changes in gliomas. Curr Opin Oncol 16:607-613. doi: 10.1097/01.cco.0000142485.81849.cc
37. Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947. doi: 10.1038/nrc1503
38. Castellino RC, Durden DL (2007) Mechanisms of disease: The PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 3:682-693. doi: 10.1038/ncpneuro0661
39. Cancer Genome Atlas (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068. doi: 10.1038/nature07385
40. Du J, Bernasconi P, Clauser KR et al (2009) Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27:77-83. doi: 10.1038/nbt.1513
41. Chi AS, Wen PY (2007) Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 11:473-496. doi: 10.1517/14728222.11.4.473
42. Gonzalez J, De GJ (2008) Combination therapy for malignant glioma based on PTEN status. Expert Rev Anticancer Ther 8:1767-1779. doi: 10.1586/ 14737140.8.11.1767
43. Lutz MP, Esser IB, Flossmann-Kast BB et al (1998) Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243:503-508. doi: 10.1006/bbrc.1997.8043
44. Zeng L, Si X, Yu WP et al (2003) PTP alpha regulates integrin-stimulated FAK autophosphorylation and cytoskeletal rearrangement in cell spreading and migration. J Cell Biol 160:137-146. doi: 10.1083/jcb.200206049
45. Irby RB, Mao W, Coppola D et al (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187-190. doi: 10.1038/5971
46. Weissenberger J, Steinbach JP, Malin G et al (1997) Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 14:2005-2013. doi: 10.1038/sj.onc.1201168
47. Bowman T, Broome MA, Sinibaldi D et al (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci USA 98:7319-7324. doi: 10.1073/ pnas.131568898
48. De Mali KA, Godwin SL, Soltoff SP et al (1999) Multiple roles for Src in a PDGF-stimulated cell. Exp Cell Res 253:271-279. doi: 10.1006/ excr.1999.4669
49. Landgren E, Blume-Jensen P, Courtneidge SA et al (1995) Fibroblast growth factor receptor-1 regulation of Src family kinases. Oncogene 10:2027-2035
50. Mao W, Irby R, Coppola D et al (1997) Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene 15:3083-3090. doi: 10.1038/sj.onc.1201496
51. Park CM, Park MJ, Kwak HJ et al (2006) Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66:8511-8519. doi: 10.1158/0008-5472.CAN-05-4340
52. Conway AM, Rakhit S, Pyne S et al (1999) Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: Role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase. Biochem J 337(Pt 2):171-177. doi: 10.1042/0264-6021:3370171
53. Furstoss O, Dorey K, Simon V et al (2002) c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J 21:514-524. doi: 10.1093/emboj/21.4.514
54. Kitagawa D, Tanemura S, Ohata S et al (2002) Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation. Its implication in an anti-apoptotic function. J Biol Chem 277:366-371. doi: 10.1074/ jbc.M107110200
55. Cox BD, Natarajan M, Stettner MR et al (2006) New concepts regarding focal adhesion kinase promotion of cell migration and proliferation. J Cell Biochem 99:35-52. doi: 10.1002/jcb.20956
56. Band CJ, Mounier C, Posner BI (1999) Epidermal growth factor and insulin-induced deoxyribonucleic acid synthesis in primary rat hepatocytes is phosphatidylinositol 3-kinase dependent and dissociated from protooncogene induction. Endocrinology 140:5626-5634. doi: 10.1210/ en.140.12.5626
57. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470-480. doi: 10.1038/nrc1366
58. Noritake H, Miyamori H, Goto C et al (1999) Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src. Clin Exp Metastasis 17:105-110. doi: 10.1023/ A:1006596620406
59. Hsia DA, Mitra SK, Hauck CR et al (2003) Differential regulation of cell motility and invasion by FAK. J Cell Biol 160:753-767. doi: 10.1083/ jcb.200212114
60. Stettner MR, Wang W, Nabors LB et al (2005) Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 65:5535-5543. doi: 10.1158/0008-5472.CAN-04-3688
61. Ding Q, Stewart J Jr, Olman MA et al (2003) The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J Biol Chem 278:39882-39891. doi: 10.1074/jbc.M304685200
62. Nomura N, Nomura M, Sugiyama K et al (2007) Src regulates phorbol 12-myristate 13-acetate-activated PKC-induced migration via Cas/Crk/Rac1 signaling pathway in glioblastoma cells. Int J Mol Med 20:511-519
63. Milano V, LaFortune T, de Groot JF (2008) Dasatinib-induced authophagy is synergistically enhanced in combination with temozolomide and is further augmented in PTEN-functional glioma. In: Proceedings of the 99th annual meeting of the American association for cancer research, Apr 12-16, 2008; San Diego, CA
64. Dey N, Crosswell HE, De P et al. (2008) The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68:1862-1871. doi: 10.1158/0008-5472.CAN-07-1182
65. Simpson L, Parsons R (2001) PTEN: Life as a tumor suppressor. Exp Cell Res 264:29-41. doi: 10.1006/excr.2000.5130
66. Edwards J, Krishna NS, Witton CJ et al (2003) Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin Cancer Res 9:5271-5281
67. Kleber S, Sancho-Martinez I, Wiestler B et al (2008) Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 13:235-248. doi: 10.1016/j.ccr.2008.02.003
68. Lund CV, Nguyen MT, Owens GC et al (2006) Reduced glioma infiltration in Src-deficient mice. J Neurooncol 78:19-29. doi: 10.1007/s11060-005-9068-y
69. Dancey JE, Freidlin B (2003) Targeting epidermal growth factor receptor - Are we missing the mark? Lancet 362:62-64. doi: 10.1016/ S0140-6736(03)13810-X
70. Paugh BS, Paugh SW, Bryan L et al (2008) EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells. FASEB J 22:455-465. doi: 10.1096/fj.07-8276com
71. Schaller MD, Hildebrand JD, Shannon JD et al (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14:1680-1688
72. Natarajan M, Hecker TP, Gladson CL (2003) FAK signaling in anaplastic astrocytoma and glioblastoma tumors. Cancer J 9:126-133. doi: 10.1097/ 00130404-200303000-00008
73. Westhoff MA, Serrels B, Fincham VJ et al (2004) SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol Cell Biol 24:8113-8133. doi: 10.1128/ MCB.24.18.8113-8133.2004
74. Mukhopadhyay D, Tsiokas L, Zhou XM et al (1995) Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 375:577-581. doi: 10.1038/375577a0
75. Kilarski WW, Jura N, Gerwins P (2003) Inactivation of Src family kinases inhibits angiogenesis in vivo: Implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res 291:70-82. doi: 10.1016/S0014-4827(03)00374-4
76. Laird AD, Li G, Moss KG et al. (2003) Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2:461-469
77. Angers-Loustau A, Hering R, Werbowetski TE et al (2004) SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. Mol Cancer Res 2:595-605
78. de Bouard S, Herlin P, Christensen JG et al (2007) Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol 9:412-423. doi: 10.1215/15228517-2007-024
79. Lee FY, Wen ML, Bhide R et al (2005) Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 106:ABstract 1994
80. Lombardo LJ, Lee FY, Chen P et al (2004) Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658-6661. doi: 10.1021/ jm049486a
81. Schittenhelm MM, Shiraga S, Schroeder A et al (2006) Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 66:473-481. doi: 10.1158/0008-5472.CAN-05-2050
82. Shah NP, Lee FY, Luo R et al (2006) Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis. Blood 108:286-291. doi: 10.1182/blood-2005-10-3969
83. Yu EY, Massard C, Gross M et al (2009) A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CA180085). J Clin Oncol (ASCO Genitourinary Cancers Symposium Abstracts) (abstract 165)
84. Kopetz S, Wolff RA, Glover K et al (2008) Phase I study of Src inhibition with dasatinib in combination with 5-fluoruracil, leucovorin, oxaliplatin (FOLFOX) and cetuximab in metastatic colorectal cancer. J Clin Oncol (ASCO Gastrointestinal Cancers Symposium Abstracts) (abstract 325)
85. Bristol-Myers Squibb (2009) Synopsis: Final Clinical Study Report for CA180021. Available at http://ctr.bms.com/pdf//CA180021.pdf. Accessed Mar 2009
86. Bristol-Myers Squibb (2009) Synopsis: Final Clinical Study Report for CA180003. Available at http://ctr.bms.com/pdf/CA180003.pdf. Accessed Mar 2009
87. Finn RS, Bengala C, Ibrahim N et al (2008) Phase II trial of dasatinib in triple-negative breast cancer: Results of study CA180059. 31st Annual San Antonio Breast Cancer Symposium, 10-14 Dec, 2008 (abstract 3118)
88. Milano V, Piao Y, La Fortune T et al (2009) Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 8:394-406. doi: 10.1158/1535-7163.MCT-08-0669
89. Cuneo KC, Geng L, Tan J et al (2006) SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. Int J Radiat Oncol Biol Phys 64:1197-1203. doi: 10.1016/j.ijrobp.2005.11.014
90. Takayama N, Sato N, O'Brien SG et al (2002) Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 119:106-108. doi: 10.1046/j.1365-2141.2002.03881.x
91. Bihorel S, Camenisch G, Lemaire M et al (2007) Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 102:1749-1757. doi: 10.1111/j.1471-4159.2007.04808.x
92. Decleves X, Bihorel S, Debray M et al (2008) ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res 57:214-222. doi: 10.1016/j.phrs.2008.01.006
93. Mahon FX, Hayette S, Lagarde V et al (2008) Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68:9809-9816. doi: 10.1158/0008-5472.CAN-08-1008
94. Porkka K, Koskenvesa P, Lundan T et al (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 112:1005-1012. doi: 10.1182/blood-2008-02-140665
95. Cloughesy TF, Yoshimoto K, Nghiemphu P et al (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8. doi: 10.1371/ journal.pmed.0050008
96. Lassman A, Wang M, Glibert M et al (2008) Phase ii trial of dasatinib for recurrent glioblastoma (rtog 0627). Neuro Oncol 10:824
97. Huang F, Reeves K, Han X et al (2007) Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 67:2226-2238. doi: 10.1158/ 0008-5472.CAN-06-3633
98. Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5:649-659. doi: 10.1038/nrd2089
99. Maa MC, Leu TH, McCarley DJ et al (1995) Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 92:6981-6985. doi: 10.1073/pnas.92.15.6981
100. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603. doi: 10.1038/nrc2442
101. Stommel JM, Kimmelman AC, Ying H et al (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290. doi: 10.1126/science.1142946